Introduction {#S5}
============

Browning of white adipose tissue has garnered interest in research on obesity because it engenders adaptive thermogenesis, a process mediated by mitochondrial uncoupling protein 1 (UCP1). When activated, UCP1 short circuits the electrochemical gradient that drives ATP synthesis. Downregulation of the proton gradient stimulates respiratory chain activity and provokes heat production through combustion of available substrates ([@R1]). This type of metabolically active and energy dissipating tissue offers a potential solution to counteract excessive fat accumulation, especially since brown adipose tissue is typically low in humans and inversely correlates with body mass index ([@R2]). The browning of adipose tissue may also modulate systemic insulin action through non-thermogenic mechanisms such as the secretion of insulin sensitizing factors from adipose tissue ([@R1]). Thus, the therapeutic potential of brown fat transcends obesity and may be considered for other metabolic abnormalities such as insulin resistance.

Carbohydrate response element binding protein (ChREBP) is a transcription factor that is known to be expressed as α and β alternatively spliced isoforms. In humans, expression of both isoforms in white adipose tissue correlates with insulin sensitivity; ([@R3], [@R4], [@R5]) but, obesity is associated with a specific reduction in ChREBPβ expression ([@R3], [@R5]). Overexpression of ChREBP in mice fed a western diet enhances systemic insulin sensitivity, reduces fat mass and increases expression of the genes associated with thermogenesis suggesting a role for ChREBP in whole body insulin sensitivity and brown adipose tissue function ([@R6]). To date, the only compound known to stimulate ChREBP expression (in mouse adipose tissue) is the incretin mimetic liraglutide ([@R7]).

Strategies to enhance adipose tissue glucose uptake and restore depleted levels of ChREBP expression can be particularly beneficial to individuals with obesity and insulin resistance. Naringenin a citrus flavonoid, reduces diet-induced weight gain, increases energy expenditure, and improves glucose and lipid metabolism in animal models ([@R8], [@R9], [@R10], [@R11], [@R12]). Activation of adenosine monophosphate-activated kinase (AMPK), regulation of insulin signaling pathways and lipid metabolism, relief from oxidative stress in pancreatic beta cells, and increases in brown fat thermogenic gene expression are among the mechanisms that have been implicated ([@R8], [@R9], [@R10], [@R11]). The effects of naringenin on energy expenditure and expression of the genes involved in glucose metabolism in human adipose tissue have not been investigated.

The literature is replete with the beneficial effects of naringenin in obesity, cardiovascular disease, and cancer ([@R13]). However, grapefruit has been shown to increase the bioavailability of drugs administered orally. Several compounds in grapefruit including the flavonoids (naringin and naringenin), furanocoumarins and sesquiterpens have been implicated ([@R14]). Naringenin being polyphenolic and high in electrons, can theoretically inhibit cytochrome P450 enzymes and enhance the bioavailability of medications including statins. Although inhibition of the cytochrome P450 enzyme system has been demonstrated in vitro and in rodent models, the results of in vivo studies in humans suggest that naringenin is not the main inhibitory compound in grapefruit ([@R15], [@R16]). The most potent inhibitor of CYP3A4, the main enzyme in the cytochrome P450 family that is involved in drug metabolism is bergapten, a furanocoumarin derivative ([@R17]).

We investigated the effects of naringenin on energy expenditure in human adipocytes, and primary human white adipose tissue. Preliminary studies demonstrated that exposure of human adipocytes to naringenin upregulated the mRNA expression of UCP1 and GLUT4. We therefore hypothesized that naringenin acts in white adipose tissue to promote conversion of human white adipocytes to the beige/brown phenotype.

Materials and Methods {#S6}
=====================

Materials {#S7}
---------

Hyclone™ Dulbecco's Modified Eagle Medium/Ham's F12 (DMEM/F12 1:1) and Gibco™ fetal bovine serum (FBS) were purchased from ThermoFisher Scientific (Waltham, MA), Rosiglitazone was purchased from AK Scientific (Union City, CA). All other reagents used in the medium were purchased from Sigma-Aldrich (St. Louis, MO). Naringenin (purity ≥ 98%) was purchased from Cayman Chemicals (Ann Arbor, MI). Protease and phosphatase were purchased from Cell Signaling Technology (Danvers, MA), RIPA buffer from Sigma, TGX protein gels from BIO-RAD (Hercules, CA). Seahorse Assay Medium and sodium pyruvate were purchased from Agilent (Santa Clara, CA). carbonyl cyanide-4-(trifluoromethoxy) phenyhydrazone (FCCP), Oligomycin, and Antimycin A were purchased from Sigma-Aldrich.

Cell Culture (Adipocytes) {#S8}
-------------------------

Human adipose-derived stem cells from overweight and obese female donors were purchased from LaCell, LLC (New Orleans, Louisiana). Preadipocytes were seeded in DMEM/F12 1:1 supplemented with 10% FBS and 1% antibiotic (penicillin/streptomycin/amphotericin). One day after reaching confluence, cells were differentiated (hADSC) in media containing 70% DMEM and 30% DMEM/F12 1:1 supplemented with 3% FBS, 1% antibiotic, 1μM dexamethasone, 33uM biotin, 0.1μM insulin, 20μM pantothenate, 5μM rosiglitazone and 500μM 3-isobutylmethylxanthine. After induction in the differentiation media (4 or 5 days), cells were maintained in medium composed of 70% DMEM and 30% DMEM/F12 1:1 supplemented with 3% FBS, 1μM dexamethasone, 33μM biotin, 0.1μM insulin, and 20μM pantothenate (Day 0). Cells were kept at 37°C in a humidified atmosphere of 95% air and 5% CO~2~. Treatments (naringenin 8μM based on pharmacokinetic study done in humans ([@R18])) started from Day 3, were administered every two days over a period of 6 days, and cells were harvested the following day (Day 10). Dexamethasone was removed from the maintenance medium during treatment to promote browning of adipocytes, ([@R19]) and FBS was inactivated by heating for 30 minutes at 56°C. Following harvest, Trizol reagent was added to lyse adipocytes and the contents of each well were homogenized. RNeasy Mini Kit (Qiagen, Germantown, MD) was used to isolate RNA following manufacturer's protocol.

Ex Vivo Adipose Tissue Explants {#S9}
-------------------------------

Abdominal subcutaneous adipose tissue (pWAT) procured from four females, subjects 1, 2, 3, and 4 undergoing elective panniculectomies was mechanically minced into 0.5--1mm diameter segments and 500μl was suspended in 3ml adipocyte maintenance medium for each replicate (Day 0). Treatments (naringenin 8μM) started from Day 3, were administered to subjects 1, 2, and 3 every two days over a period of 14 days or were started at Day 10 and treated over 7 days. All pWAT samples including the untreated controls were harvested on the same day. In a separate experiment pWAT from subjects 1, 2, and 4 were treated in a similar fashion with GW 7647 (0.3μM). At the end of the treatment period, adipocytes were isolated from pWAT after standard collagenase digestion and RNA was extracted with Trizol. Subject characteristics are provided in [Table 2](#T2){ref-type="table"}.

Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) {#S10}
----------------------------------------------------------

The RNA was quantified using Invitrogen Qubit RNA broad range assay kit and read using Qubit Fluorometer (ThermoFisher Scientific). Reverse transcriptase and PCR was conducted in one reaction with the reverse PCR primer priming cDNA synthesis using SuperScript® III Platinum One-Step Quantitative RT-PCR System with Rox from Invitrogen (ThermoFisher Scientific). Amplicons were designed to span an intron-exon junctions to avoid amplification of genomic sequences. Primer and probe oligonucleotide sets were purchased from Integrated DNA Technologies (Coralville, IOWA) and are provided in [Table 1](#T1){ref-type="table"}. RPL13A (Taqman® ID Hs04194366_g1, Thermofisher Scientific, Waltham, MA.) was used as a housekeeping gene. The RT-PCR assay for each sample was conducted in duplicate using the protocol for Applied Biosystems Instruments (7900 HT), with the exception that an extension temperature of 61°C was used in the assay to measure ChREBPβ.

Western Blots {#S11}
-------------

Cells from three donors treated with naringenin at 10μM for six days or untreated controls were lysed in RIPA buffer containing a cocktail of protease and phosphatase. TGX SDS-PAGE gels (Any Kd™, BioRad) were used to separate 50μg of solubilized protein per sample. Following transfer, nitrocellulose membranes were probed overnight at 4°C with primary antibodies against UCP1 (\#MAB6158, R&D Systems), GLUT4 (\#sc-53566, Santa Cruz), ChREBP (\#sc515922, Santa Cruz), AMPK (\#2535S, Cell Signaling Technology, CST), p-AMPK (T-172, \#2532S, CST), and β-Actin (A5316, Sigma). HRP-linked anti-rabbit (12--348, Sigma) and anti-mouse (AP130P, Sigma) were used to detect specific antibody-antigen complexes. Proteins were visualized by chemiluminescence (Western Lightning Plus-ECL, PerkinElmer, Waltham, MA). Densitometric analyses were performed using Image J software (National Institutes of Health) ) and the relative expression of the target protein versus β-actin was calculated.

Mitochondrial Bioenergetics {#S12}
---------------------------

To study mitochondrial bioenergetics in human white adiopocytes, a SeaHorse XF24 Extracellular Flux Analyzer (SeaHorse Bioscience, Billerica, MA) was used. The human adipose-derived stem cells were seeded onto the SeaHorse XF24 V7 plate. The protocol for evaluating the bioenergetics parameters of the adipocytes is previously described ([@R20]). Briefly, sequential injections of oligomycin (2 μM) to inhibit ATP synthase, carbonyl cyanide-4(trifluoromethoxy) phenyhydrazone (FCCP, 2 μM), to uncouple electron transport and allow for maximum electron flux through the electron transport chain, and antimycin A (1.5 μg/mL), to inhibit complex III were used to determine oxygen consumption rate (OCR). Basal OCR is measured before any injections. The difference between basal OCR and respiration that results when Oligomycin is injected reflects ATP-linked OCR. Following FCCP injection, maximal OCR is measured, and the difference between this value and basal OCR reflects the reserve capacity. Non-mitochondrial OCR is measured after injecting Antimycin A and the difference between this value and OCR that results from inhibition of ATP synthase by Oligomycin is the basal proton leak.

Cells were treated every other day over five days with naringenin 8 μM, rosiglitazone 0.1 μM, GW 7647 0.3 μM or were untreated controls. Prior to the assay on Day 6, 625 μl/well serum-free SeaHorse XF assay media, containing 5mM pyruvate was loaded onto the plates. Plates were equilibrated in a non-CO~2~ incubator at 37 ºC for 20 minutes before obtaining the bioenergetics profiles. Experiments included four plates (4--8 replicates) with naringenin, rosiglitazone and control as the treatments, and two plates also included GW 7647 as a treatment.

Statistical Analysis {#S13}
--------------------

A general linear model was used to perform analysis of variance (ANOVA). The primary outcomes which were differences from the control were analyzed after Welch's test of homogeneity of variances. The assumption of normality was assessed using the Shapiro-Wilks test. For data that were not normally distributed, statistical significance was verified by logarithm or square root transformations or by non-parametric analysis (Wilcoxon rank-sum test). For the seahorse data, a general linear model was used to perform ANOVA to assess the statistical significance of differences among the four treatments (naringenin, rosiglitazone, GW 7647 and control) after accounting for statistical variability in the respective outcomes that is attributable to plates. Six separate models were analyzed with each of the six outcomes (basal, ATP-linked, maximal, reserve, proton-linked and non-mitochondrial OCR) taken in turn as the dependent variable and as a linear function of models containing the explanatory variables (treatment, plates nested within treatments and wells nested within plates). The magnitude of the component of outcome variance attributable to plates was tested against the alternative of being significantly different from zero and, if there was strong evidence in favor of the alternative, the mean square for plates within treatments was used as a denominator in testing for treatment differences. If there was not strong evidence in favor of a significant component of variability attributable to plates, the mean square for wells within plates was used as a denominator in testing for treatment differences. Statistical significance of specific pairwise differences between treatments was tested by formulating specific contrasts among the four treatments. Significance was set at p \< 0.05. Outcomes are summarized as means ± SE. All analyses were performed using SAS 9.4 (SAS Institute, Cary NC).

Results {#S14}
=======

Naringenin Promotes Thermogenic Gene expression in Human Adipocytes {#S15}
-------------------------------------------------------------------

As shown in [Figure 1](#F1){ref-type="fig"}, naringenin treatment increased mRNA levels of UCP1,PGC-1α and PGC-1β. PGCs can mediate PPARγ-dependent transcriptional responses and are involved in mitochondrial biogenesis and uncoupling. PGC-1α and PGC-1β can exhibit different regulation patterns ([@R21]). Although the induction of PGC-1α was small (40% over control), the regulation was statistically significant (p = 0.013).

Fat mobilization in adipose tissue is effected by ATGL ([@R22]). We observed that ATGL mRNA increased with naringenin treatment. Expression of CPT1β, which transports fatty acids into the mitochondria, was increased by 55% over control but this regulation was statistically significant (p \<0.01). The mRNA expression of genes associated with insulin sensitivity GLUT4, ChREBP (which reflects α + β), ChREBPβ and adiponectin increased in the naringenin treated adipocytes (p \<0.01). Although SIRT1 activity increases the thermogenic capacity of white adipose tissue by mediating PRDM16 driven activation of thermogenesis ([@R23]), we did not observe any changes in the mRNA expression of SIRT1 or PRDM16 ([Figure 1](#F1){ref-type="fig"}).

Chronic AMPK activation is involved in the remodeling of adipose tissue through upregulation of pathways that favor energy dissipation ([@R24]). In hADSC, naringenin treatment increased protein expression of UCP1 (3 day: p \< 0.01, 7 day: p = 0.01), GLUT4 (3 day and 7 day: p = 0.02), ChREBP (7 day: p = 0.02) and phosphorylation of AMPK (7 day: p = 0.02) ([Figure 2](#F2){ref-type="fig"}).

In Primary Adipose Tissue the Response to Naringenin Varies Among Subjects {#S16}
--------------------------------------------------------------------------

To more closely model the response of adult white adipose tissue in vivo, pWAT was maintained in organ culture with exposure to vehicle or naringenin for seven or 14 days. There were marked differences in the response to naringenin treatment in the adipose tissues from the three different subjects. In Subject 1, mRNA expression of UCP1 did not increase. In Subject 2, there was a substantial increase in UCP1 but the variability among the samples precluded attainment of statistical significance. However, in Subject 3 the increase in UCP1 expression was statistically significant at both seven and 14 days (p = 0.008 and p = 0.001 respectively) of naringenin treatment. The expression of GLUT4 followed a similar pattern (p = 0.03 and p = 0.003 at seven and 14 days respectively). Although ChREBP is expressed in brown adipose tissue, induction of UCP1 was not accompanied by increased expression of ChREBPβ in subject 3. ChREBPβ expression increased in subjects 1 and 2 (p = 0.002 and p = 0.013 respectively) at 14 days of naringenin treatment. In pWAT of subjects 1 and 3 PGC-1α increased at days 7 and 14 respectively (p =0.04 and p = 0.02) whereas PGC-1β increased at 14 days in subjects 2 and 3 (p = 0.03 and p = 0.005 respectively). In pWAT of subjects 1 and 2 ATGL increased at days 7 and 14 respectively (p =0.02 and p = 0.003) and adiponectin increased at 14 days in pWAT of subjects 2 and 3 (p = 0.008 and p = 0.005 respectively ([Figure 3](#F3){ref-type="fig"}).

In pWAT from three subjects (including subjects 1, 2, and 4) we examined the mRNA expression of UCP1 and GLUT4 following treatment with the pharmacologic PPARα agonist GW 7647. Similar to the naringenin treatment, in pWAT from the subject 1 there was no increase in the mRNA expression of UCP1 and GLUT4, whereas in pWAT from subject 2 there was a significant increase in UCP1 (p = 0.003 and p = 0.004 at 7 and 14 days respectively) and substantial increase in GLUT4, but this regulation was not statistically significant ([Figure 4](#F4){ref-type="fig"}).

Naringenin Increases Energy Expenditure {#S17}
---------------------------------------

As shown in [Figure 5](#F5){ref-type="fig"}, naringenin increased basal, ATP-linked, maximal, and reserve OCR in intact adipocytes compared to controls (p \< 0.01). Basal proton linked OCR and nonmitochondrial OCR were not significantly different between vehicle and treatment groups. ATPlinked, maximal, reserve and proton-linked respiration in human adipocytes exposed to naringenin was similar to the positive controls, rosiglitazone and GW 7647 (p \> 0.05).

Discussion {#S18}
==========

Pharmacologic browning of fat correlates with resistance to high-fat diet induced obesity and insulin resistance. In our study we demonstrated an increase in the mRNA and protein expression of UCP1, GLUT4, and ChREBP, the genes involved in thermogenesis and insulin sensitivity, when hADSC were treated with naringenin at concentrations that are physiologically attainable in humans ([@R18]). Naringenin also stimulated mRNA expression of PGC-1 α and β (nuclear receptor co-activators involved in thermogenesis), ATGL and CPT1β (key enzymes necessary for fat oxidation), and adiponectin (insulin-sensitizing adipokine), in addition to increasing OCR.

In pWAT maintained ex vivo, the response was varied among the adipose tissue obtained from three overweight female subjects. UCP1 and GLUT4 expression significantly increased in one of the three subjects which was accompanied by an increase in the expression of PGC-1α and PGC-1β. However, expression of ChREBP and ChREBPβ increased in pWAT of the subjects that did not manifest an increase in UCP1 and GLUT4. Interestingly, the lack of any change in UCP1 and GLUT4 expression in response to naringenin treatment in pWAT of subject 1 was also seen when this pWAT was treated with GW 7647, a potent pharmacologic PPARα agonist. In human adipocytes PPARα upregulates the expression of the genes involved in lipid metabolism and increases maximal OCR ([@R25]). Since naringenin activates PPARα ([@R10]), it is likely that PPARα plays an important role in the thermogenic effect of naringenin but some humans may not be responders to this pathway. However, the notion bears investigation with larger sample sizes.

Browning of human adipocytes is induced by pharmacologic PPARα and γ agonists, GW 7647 and rosiglitazone respectively, through activation of a comprehensive gene program that leads to increased mitochondrial function and energy consumption ([@R19], [@R26], [@R27]). Naringenin is an activator of PPARα and γ ([@R10]). In mice, naringenin has been shown to increase energy expenditure, upregulate UCP1 in brown fat, and promote the induction of fat oxidation ([@R12], [@R28]). Our in vitro studies in human adipocytes suggest that naringenin may induce a browning of human white adipose tissue through an upregulation of UCP1 (Figures [1](#F1){ref-type="fig"} -- [3](#F3){ref-type="fig"}) and an increase in OCR ([Figure 5](#F5){ref-type="fig"}). Additionally, the expression of the PPARγ co-activators PGC1α and β were stimulated in human adipocytes and pWAT. Both members of the PGC1 family are important for mitochondrial oxidative metabolism, although differences in their interactions with other transcription factors mediate differences in their functional specificity ([@R29]).

The relevance of increased energy consumption induced by browning to human physiology may be debatable, but its effects on glucose metabolism have physiologic significance. In humans, approximately 70 ml of brown fat can clear 20--25 g of glucose from circulation in 24 hours ([@R30]). Our in vitro studies in human adipocytes clearly demonstrate that naringenin increases expression of ChREBP, ChREBPβ, and GLUT4. In white adipose tissue, the transcriptional targets of ChREBP include the genes involved in adipocyte differentiation, lipid metabolism, and browning ([@R6]). Mice with adipose-specific GLUT4 overexpression display improved glucose control, and upregulation of ChREBP expression ([@R4]). In humans grouped according to their two-hour blood glucose concentrations, the expression of GLUT4 and ChREBP measured in subcutaneous fat biopsies decreased as blood glucose concentrations rose across the groups ([@R5]). Interestingly, expression of adipose ChREBP correlated positively with expression of GLUT4 and insulin sensitivity ([@R5]). Although the study was done in obese adolescents, it provides preliminary evidence that in humans, ChREBP, ChREBPβ, and GLUT4 gene expression correlate with physiologic outcomes related to glucose homeostasis. Secretion of adipokines such as adiponectin is another key role of adipose tissue that contributes to whole body insulin sensitivity ([@R31]). Thiazolidinediones (TZDs) are PPARγ agonists that increase insulin sensitivity at least in part through an increase in adiponectin secretion ([@R32]). In the promoter region of the human adiponectin gene a PPAR-responsive element has been identified and is thought to be the mechanism by which TZDs increase plasma adiponectin. ([@R33]) In our study, naringenin treatment increased adiponectin mRNA expression suggesting a role for naringenin in protecting against insulin resistance.

Shortage of cellular energy stores marked by an increase in AMP levels and a decline in ATP levels activates AMPK which then initiates cellular programs that increase catabolism, mostly by enhancing oxidative metabolism and mitochondrial biogenesis ([@R34]). Activation of AMPK increases UCP1 and induces an accumulation of brown adipocytes in murine WAT ([@R35]). Naringenin promotes glucose homeostasis in animal models through activation of AMPK signaling in the liver, skeletal muscle, and in macrophages differentiated from the human cell line THP-1 ([@R36]). In our study, activation of AMPK was stimulated in human adipocytes treated with naringenin ([Figure 2](#F2){ref-type="fig"}). Consistent with the activation of AMPK and increase in catabolism, our studies show that naringenin increases mRNA expression of ATGL in hADSC and pWAT. Catabolism of fatty acids from triglyceride stores is the function of lipolytic enzymes, particularly ATGL which catalyzes the initial step in triglyceride hydrolysis ([@R22]).

The distinctive function of brown adipocytes is thermogenic energy expenditure, propelled by the catabolic breakdown of lipids. Therefore, to distinguish between white adipocytes and those that have potentially acquired a brown/beige phenotype, we extended our characterization to the mitochondrial function of naringenin-treated adipocytes by analyzing OCR. Basal OCR and ATP-linked OCR were higher in the naringenin-treated cells compared to the control or untreated cells. To functionally determine browning in hADS, higher substrate oxidation capacity than controls must be demonstrated as would be reflected by substantial increases in maximal respiration rate. Following sequential injection of compounds that modulate mitochondrial function, naringenin increased maximal respiratory capacity and this increase was not different from the positive controls rosiglitazone and GW 7647. However, induction of UCP1 following treatment with naringenin is by far lower than that of rosiglitazone, in the adipocytes ([@R37]).Therefore, the increase in energy expenditure may not be completely mediated by UCP1. Proton leak was not significantly different between naringenin and control. UCP1 is not inherently active in the mitochondria and is activated by fatty acids. In intact cells, proton leak represents basal uncoupled respiration. In rodent adipocytes, injecting isoproterenol during the OCR measurement stimulates an adrenergic response and UCP1-mediated proton leak can be determined ([@R38]). However, in human adipocytes from obese individuals the response to βadrenergic stimulation by isoproterenol is impaired ([@R39]).

Conclusions {#S19}
===========

Robust data from rodent studies and in vitro models demonstrate that naringenin increases energy expenditure and improves glucose metabolism. Although our study in hADSC and pWAT builds upon this data, it demonstrates that the response to naringenin may differ among human subjects based on their response to pathways that activate energy expenditure. The results warrant further investigation to determine their clinical relevance.

This publication was supported in part by the National Center For Complementary & Integrative Health and the Office of Dietary Supplements of the National Institutes of Health under Award Number P50AT002776 which funds the Botanical Dietary Supplements Research Center of Pennington Biomedical Research Center, in part on work that was supported by the National Institutes of Health under Award Number T32 A T004094 and in part by 1 U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health which funds the Louisiana Clinical and Translational Science Center. This work utilized the facilities of the Genomics Core that are supported in part by COBRE (NIH8 1P30GM118430--01) and NORC (P30DK072476) center grants from the National Institutes of Health.

Disclosure: The authors declare no conflict of interest

![qRT-PCR in Human Adipocytes Treated with Naringenin\
qRT-PCR assays for mRNA expression conducted in duplicates following naringenin treatment of hADSC for seven days compared to untreated hADSC (Control): uncoupling protein 1 (UCP1, n = 26), adipose triglyceride lipase (ATGL, n = 12), carnitine palmitoyltransferase 1β (n = 16), glucose transporter type 4 (GLUT4, n = 16), carbohydrate response element binding protein α + β (ChREBP, n = 12), ChREBP beta isoform (ChREBPβ, n = 12), adiponectin (n = 12), sirtuin 1(SIRT1, n = 4), PR domain containing 16 (PRDM 16, n = 12), peroxisome proliferator-activated receptor gamma coactivator-1alpha/beta (PGC-1α/β, n = 12). The results are presented as mean ± SE, \*\*p \< 0.01 compared to respective controls. Each experiment was conducted with four samples except for measurement of UCP1 mRNA that had four or six samples.](nihms-1508932-f0001){#F1}

![Immunoblotting in Human Adipocytes Treated with Naringenin\
Human adipocytes from three donors were treated with naringenin for three or seven days. (a) Cellular protein was extracted and Western blot analysis was used to detect protein levels of UCP1, GLUT4, ChREBP, and phosphorylation levels of AMP-activated protein kinase (AMPK) in the untreated control (C) after three days (3d) and seven days (7d) of naringenin treatment. (b) Densitometric analysis](nihms-1508932-f0002){#F2}

###### qRT-PCR in Primary Human Adipose Tissue Treated with Naringenin

qRT-PCR assays for mRNA expression conducted in duplicates following naringenin treatment of quadruplicate pWAT samples, from three overweight female donors, for seven and 14 days compared to untreated pWAT (Control): **a)** uncoupling protein 1 (UCP1) **b)** adipose triglyceride lipase (ATGL) **c)** peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) **d)** PGC-1 beta (PGC-1β) e) glucose transporter type 4 (GLUT4) **e)** Adiponectin **f)** carbohydrate response element binding protein α + β (ChREBP) **g)** ChREBP beta isoform (ChREBPβ), \*\*p \< 0.01. The results are presented as mean ± SE, \*p \< 0.05 compared to respective control.

![](nihms-1508932-f0003)

![](nihms-1508932-f0004)

![qRT-PCR in Primary Human Adipose Tissue Treated with GW 7647\
qRT-PCR assays for mRNA expression conducted in duplicates following GW 7647 (pharmacologic PPARα agonist) treatment of quadruplicate pWAT samples, from three overweight female donors, for seven and 14 days compared to untreated pWAT (Control): **a)** uncoupling protein 1 (UCP1) **b)** glucose transporter type 4 (GLUT4). The results are presented as mean ± SE, \*\*p \< 0.01 compared to respective control.](nihms-1508932-f0005){#F4}

![Oxygen Consumption Rate in Human Adipocytes Treated with Naringenin\
Oxygen consumption rate (OCR) was measured in mature human adipocytes that were grown in four SeaHorse XF24 V7 plates. Cells were treated for six days with naringenin, rosiglitazone, GW 7647 or were untreated controls. Measurements include basal OCR, ATP⁰ linked OCR after inhibition of ATP synthase by oligomycin, maximal respiratory rate and reserve capacity after artificial uncoupling by FCCP, non-mitochondrial respiration after inhibition of complex III by antimycin A, and proton-linked OCR. Basal, ATP-linked, maximal and reserve OCR were significantly different between the naringenin-treated cells and the untreated controls. ATP-linked, maximal, reserve, and proton-linked OCR were not significantly different (p \> 0.05) between naringenin and the positive controls rosiglitazone and GW 7647. The results are presented as mean ± SE, \*\*p \< 0.01 compared to control.](nihms-1508932-f0006){#F5}

###### 

sPrimer and probe sequences for qPCR

  Gene          Primer and Probe   Sequences                    NCBI Reference Sequence
  ------------- ------------------ ---------------------------- -------------------------
  Adiponectin   Forward            CTGGTGAGAAGGGTGAGAAAG        NM_004797.2
                Reverse            CTCCTTTCCTGCCTTGGATT         
                Probe              TGGTCCTAAGGGAGACATCGGTGA     
  ATGL          Forward            CGTGTACTGTGGGCTCATC          NM_020376.3
                Reverse            GGACACTGTGATGGTGTTCTTA       
                Probe              ATGGTGGCATTTCAGACAACCTGC     
  CPT-1β        Forward            TACCATGGGTGGATGTTTGAG        NM_013261.3
                Reverse            GTCTGGAAGCTGTAGAGCATAG       
                Probe              TCTGGGCTATGTGTATCCGCCTTCTA   
  ChREBP        Forward            TCT GGA CAC AGC CGT CT       NM_032951
                Reverse            GCT TGG GGT CTT CAG GAA      
                Probe              ATCAGAACTCAGGAAGGCGCTGG      
  ChREBPβ       Forward            GAGCGGATTCCAGGTGAG           BG616809.1
                Reverse            TTGTTCAGGCGGATCTTGT          
                Probe              TCATCAGTGGCAAGCTGGTGTCTC     
  GLUT4         Forward            GTATCATCTCTCAGTGGCTTGG       NM_001042
                Reverse            ATAGGAGGCAGCAGCATTG          
                Probe              AAAGGGCCATGCTGGTCAACAATG     
  PGC-1α        Forward            CACCAAACCCACAGAGAACA         NM_00145134.1
                Reverse            GGGTCAGAGGAAGAGATAAAGTTG     
                Probe              AAAGAAGTCCCACACACAGTCGCA     
  PGC-1β        Forward            GAGGCGCTTTGAAGTGTTTG         NM_001172699
                Reverse            GAACACCGGTAGGTGATGAAG        
                Probe              CAGCACCTCGCACTCCTCAATCTC     
  PRDM16        Forward            TCGGAAATCAGAAACTTTATTGCC     NM_199454
                Reverse            TCCTGCTTCTCACTGGCTA          
                Probe              TCTCTGTTCGCGTTGATGCTTGGT     
  SIRT1         Forward            GTTTCATGATAGCAAGCGGTTC       NM_001142498
                Reverse            GTCATGGTTCCTTTGCAACAG        
                Probe              CTCGATGTCCTAGGTGCCCAGC       
  UCP1          Forward            GAGGAGTGGCAGTATTCATTGG       NM_021833
                Reverse            CCGTGTAGCGAGGTTTGATT         
                Probe              TTCAAGCACAGAGCCATCTCCACG     

National Center for Biotechnology Information (NCBI), Adipose triglyceride lipase (ATGL), Carnitine palmitoyltransferase 1B (CPT-1B), carbohydrate response element binding protein (alpha+beta, ChReBP), ChREBP beta (ChREBPβ), glucose transporter type 4 (GLUT4), peroxisome proliferator-activated receptor gamma coactivator 1-alpha/beta(PGC-1α/β), PR domain containing protein (PRDM16), sirtuin 1 (SIRT1), uncoupling protein 1 (UCP1)

###### 

Characteristics of donors of adipose tissue used in the explant experiments

  Subject   Age   BMI    Race
  --------- ----- ------ ------------------
  1         33    29.2   Caucasian
  2         45    25.8   Caucasian
  3         39    29.3   African American
  4         35    26.1   African American

###### What is known about this subject?

-   Naringenin, a citrus flavonoid, increases insulin sensitivity and improves glucose and lipid metabolism in animal and in vitro models.

-   Naringenin activates brown fat and increases energy expenditure in mice.

-   The improvements in glucose and lipid metabolism have been attributed to the antioxidant effects of naringenin, increase in glucose uptake in muscle, reduction in hepatic glucose production, and lowering of plasma lipids.

###### What does this study add?

-   In humans, naringenin is a potential therapeutic agent targeting energy expenditure.

-   Our study builds upon robust data from rodent studies showing that naringenin improves glucose metabolism, but proposes for the first time adipose tissue as the site of mechanistic action in humans.

-   Our study demonstrates that the response to naringenin may differ among human subjects based on their response to pathways that activate energy expenditure.
